A systematic review of 17 studies involving over 2,000 women found sexual dysfunction affects approximately 37% of ovarian cancer patients, though prevalence estimates vary widely depending on study design and sample characteristics. The finding underscores a significant but under-addressed quality-of-life concern in cancer survivorship.
Researchers conducted a meta-analysis of observational studies published through November 2023 examining sexual dysfunction prevalence in women with ovarian cancer. After screening databases including PubMed, ScienceDirect, Scopus, Web of Science, Embase, and Google Scholar, they identified 17 studies meeting inclusion criteria: observational designs (cross-sectional, cohort, or case-control), full English-language publications, and specific data on sexual dysfunction prevalence. The combined analysis represented 2,018 women across these studies.
The meta-analysis calculated a global prevalence estimate of 37% (95% confidence interval: 21.7-55.4%) for sexual dysfunction in ovarian cancer patients. The wide confidence interval indicates substantial heterogeneity across studies, meaning prevalence rates differed meaningfully depending on which population was studied and how sexual dysfunction was measured. This variation is expected given differences in cancer treatment regimens, time since diagnosis, age ranges, and assessment methods across the included research.
Two patterns emerged from meta-regression analyses. First, studies with larger sample sizes tended to report lower prevalence estimates than smaller studies, a pattern sometimes associated with publication bias or methodological differences between small and large investigations. Second, more recently conducted studies reported lower prevalence rates compared to earlier research, potentially reflecting improvements in cancer treatment protocols, better supportive care, or increased recognition and management of sexual health concerns in oncology settings.
The authors emphasize that sexual dysfunction carries substantial clinical significance for ovarian cancer survivors, noting associations with psychological distress, relationship strain, and reduced quality of life. They conclude that healthcare systems should implement specialized training and targeted interventions to address sexual health as part of comprehensive cancer survivorship care.
This research documents a previously under-quantified problem in cancer survivorship but doesn't identify specific interventions. If you or someone you know has completed ovarian cancer treatment, several practical considerations emerge from this finding:
Recognize sexual dysfunction as an expected outcome to discuss proactively. Sexual health complications following ovarian cancer stem from multiple sources: surgical removal of reproductive organs, chemotherapy effects on blood flow and hormonal balance, radiation damage to pelvic tissues, and psychological factors including trauma, body image changes, and anxiety. Unlike acute treatment side effects, sexual dysfunction often persists or develops months after treatment completion, making it easy to overlook during standard follow-up appointments.
Initiate conversations with your oncology team. Most cancer centers lack systematic sexual health screening protocols. If concerns arise, ask specifically about sexual function during survivorship visits. Gynecologic oncologists and oncology nurses increasingly recognize this as a standard quality-of-life domain, though awareness varies significantly by institution.
Seek specialized assessment if needed. Sexual dysfunction in cancer survivors is multifactorial. A qualified sex therapist, particularly one with oncology experience, can distinguish between physical factors (vaginal dryness, pelvic floor dysfunction, reduced arousal from hormonal changes) and psychological factors (trauma responses, relationship discord, depression). Some physical complications respond well to evidence-based interventions like pelvic floor physical therapy or vaginal rehabilitation techniques.
Understand that this is treatable. While the meta-analysis documents prevalence without evaluating interventions, clinical experience and emerging research indicate that sexual dysfunction in cancer survivors responds to targeted approaches combining medical management (addressing hormonal insufficiency, managing pain), psychological support, and partner communication work.
| Parameter | Details |
|---|---|
| Study type | Systematic review and meta-analysis |
| Studies included | 17 observational studies |
| Total participants | 2,018 women |
| Outcome measured | Prevalence of sexual dysfunction in ovarian cancer patients |
| Primary finding | 37% prevalence (95% CI: 21.7-55.4%) |
| Journal | Cancer Treatment and Research Communications |
| Publication date | 2024 |
| PubMed ID | 42603545 |
| Search scope | Through November 2023 |
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.